Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Indivior (INDV)

Indivior Completes Merger With Supernus to Form Combined CNS Biopharmaceutical Leader

Neutral Impact 5 of 5 m&a

Indivior and Supernus Pharmaceuticals completed their merger on November 2, 2026, forming a combined central nervous system biopharmaceutical company operating as Supernus, Inc. Legacy Indivior stockholders own approximately 56.5% of the combined company, and former Supernus stockholders own about 43.5%. The combined entity entered into a $650 million senior secured term loan facility to help fund a $1.0 billion aggregate special cash dividend to Indivior stockholders.

Key points

  • The merger was completed on November 2, 2026, creating a combined company that will trade under the ticker symbol SUPN starting November 3, 2026.
  • The combined company entered into a $650 million senior secured term loan facility with Citibank, N.A. on November 2, 2026.
  • Legacy Indivior stockholders own approximately 56.5% and former Supernus stockholders own approximately 43.5% of the combined company on a fully diluted basis.
  • Jack Khattar serves as President and CEO, and Tony Kingsley serves as Board Chair of the combined company.

The filing

CompanyIndivior (INDV)
Form8-K, current report
Filed with the SECNov 2, 2026, 9:27 AM ET
Accession number0001104659-26-121013

Items reported: 1.01 Material Definitive Agreement2.01 Acquisition or Disposition Completed2.03 New Direct Financial Obligation5.02 Director / Officer Change5.03 Bylaw / Charter Amendment7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Google Gemini, gemini-3.5-flash-lite) on Nov 2, 2026, 1:16 PM ET, from the text of the filing and its press-release exhibits only.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.